Download - Evonik Industries

More documents

Recommendations

Info

02 Contents 06 20 30 elements34 Issue 1|2011 n e W s 04 Capacity expansion planned in isophorone chemistry 04 MoU on the construction of new production plants for hydrogen peroxide and propylene oxide 05 Laurolactam capacity expansion successful 05 Korea: joint venture for the production of hydrogen peroxide evonik innovation aWard 2010 06 „And the winner is...“ neW or improved proCesses Category 08 A new route to high-purity isobutene neW produCts/neW system solutions Category 14 Bringing the power of meat back into feed: CreAMINO® for animal nutrition n e W s 18 Energy efficiency with a flat design 18 Technology in 3D: PPA for three-dimensional interconnect devices 19 Evonik and AU Optronics conclude strategic partnership 19 Protecting high-quality surfaces HealtH & nutrition 20 New technology platforms improve the bioavailability of active ingredients in tablets: a tablet instead of an injection n e W s 28 ROHACELL® successfully used in the rear-pressure bulkhead prototype of Chinese passenger jets 28 Environmentally sound production of sodium cyanide in Russia: Evonik grants licenses to EPC 29 Electrical scrap: the mother of invention designing WitH polymers 30 Competition for titanium: PEEK conquers the medical technology market n e W s 35 Lead-free—not just gasoline 35 Credits
Expansion and transition A pill or an injection? Patients don’t always have a choice. A simple tablet form of insulin, for example, would biodegrade in the gastrointestinal tract before it had a chance to work. So insulin must be injected. Other active ingredients, such as fenofibrate used to lower cholesterol, dissolve poorly and thus cannot reach the bloodstream when prescribed as a pill. And the problem is expected to worsen in the future: 95 percent of all active ingredients will have poor oral bioavailability— either because of poor solubility characteristics or because they will be „biologicals“ based on proteins and peptides, which are destroyed when they reach the intestinal tract in a pill form. Evonik is well prepared for this challenge. Our Pharma Polymers Business Line, which has a long experience in the formulation of tablets and controlled release of active ingredients with our EUDRAGIT® product line, is currently bringing new technologies to market which could spare many patients the dreaded injection. These technologies are designed to permit oral ingestion of drugs which today would need to be injected. They improve the solubility of active ingredients, increase absorption in the bloodstream, and protect against enzymes and other degradation agents. And with the acquisition of Boehringer Ingelheim’s Resomer® business, the business line now has a complementary technology platform for parenteral formulations of the kind used in injections, infusions, and longlasting depots. You can read more about our developments around pharmaceutical polymers on page 20. Another highlight of this issue are the winners of our Innovation Award 2010—an award we present to our researchers for outstanding developments in chemistry. The HPPO process, a joint development by Evonik and Uhde, and an award winner from 2004, demonstrates how truly exceptional these developments really are. The process produces extremely lowcost and ecofriendly propylene oxide from propylene and hydrogen peroxide. The idea: As the second largest manufacturers of hydrogen peroxide in the world, we are creating a completely new market by granting licenses for the HPPO process and supplying the hydrogen peroxide required for it. And the idea has paid off completely. In addition to the Korean firm SKC, which has been successfully producing an annual 100,000 metric tons of propylene oxide for the last two years, the Indian chemical company Gujarat Alkalies and Chemicals Limited is now planning to acquire a license, build a plant, and source the hydrogen peroxide from us. We are also currently negotiating the licensing of HPPO with a host of other companies. HPPO and pharma polymers are typical of our entire portfolio. They target widely differing markets that we are approaching in completely different ways. But the result is the same: a sustainable expansion of our business activities—not least because they serve the global megatrends of health and nutrition and resource efficiency. Expansion is essential in our transition to a worldwide leading specialty chemicals company. We’ve now completed the first step in that direction with the sale of 51 percent of our shares in Evonik Steag GmbH, which bundles Evonik‘s energy activities. patrik Wohlhauser Chairman of the Board of Management of Evonik Degussa GmbH editorial 03 elements34 Issue 1|2011
Page 1: elements34 Quarterly Science Newsle
Page 5 and 6: there are no significant amounts of
Page 7 and 8: evonik innovation aWard 2010 07 Evo
Page 9 and 10: evonik innovation aWard 2010 09 ele
Page 11 and 12: The simulation, on the other hand,
Page 13 and 14: in Antwerp, only part of the MTBE r
Page 15 and 16: evonik innovation aWard 2010 15 The
Page 17 and 18: establishing a suitable synthesis p
Page 19 and 20: Evonik and AU Optronics conclude st
Page 21 and 22: For over 50 years, functional polym
Page 23 and 24: Figure 2 Solid solutions can signif
Page 25 and 26: additional polymer platForm Evonik
Page 27 and 28: Figure 8 Image from a scanning elec
Page 29 and 30: In this process, the sodium cyanide
Page 31 and 32: Spinal column implant: The greater
Page 33 and 34: Evonik has proven the biocompatibil
Page 35 and 36: Lead-free—not just gasoline Histo

Download - Evonik Industries

Create successful ePaper yourself

Delete template?

Save as template?